Rheumatoid Arthritis Recruiting Phase 4 Trials for Methotrexate (DB00563)

Also known as: Rheumatoid Arthritis(RA) / Rheumatoid Arthritis, NOS / Rheumatoid Arthritis RA / Rhematoid Arthritis / Rheumatic Arthritis / Rheumatoid Arthritis (RA) / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Arthritis, Rheumatoid (RA) / Rheumatoid Arthritis(RA) / RA / Systemic rheumatoid arthritis / Rheumatoid arthritis (disorder) / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Rheumatoid arthritis NOS / Rheumatoid arthritis NOS (disorder)

DBCOND0027961 (Rheumatoid Arthritis)Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02374021Treatments Against RA and Effect on FDG-PET/CTTreatment
NCT03855007The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months TreatmentTreatment
NCT02837978The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months TreatmentTreatment
NCT03505008Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and TaiwanTreatment
NCT03492658Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)Treatment
NCT04066803Optimal MTX Dose With Folic Acid Randomized Case-control TrialTreatment
NCT03254589Methotrexate, Blood Pressure and Arterial Function in Rheumatoid ArthritisTreatment
NCT02764515Kunxian for the Treatment of Rheumatoid ArthritisTreatment